Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death[1]. Surgery is the only known curative treatment, although most newly diagnosed patients are not surgical candidates due to locally extensive and/or distant metastatic disease. Radiation therapy (RT) may benefit patients with advanced PDAC by improving local control (LC)[2], reducing pain[3], and enhancing quality-of-life (QoL)[4]. However, non-ablative RT does not provide an overall survival (OS) advantage over chemotherapy alone for borderline resectable (BRPC)[5] or locally advanced pancreas cancer (LAPC)[2].

Source: Radiotherapy and Oncology - December 20, 2023 Category: Radiology Authors: Michael D. Chuong, Percy Lee, Daniel A. Low, Joshua Kim, Kathryn E. Mittauer, Michael F Bassetti, Carri K. Glide-Hurst, Ann C. Raldow, Yingli Yang, Lorraine Portelance, Kyle R. Padgett, Bassem Zaki, Rongxiao Zhang, Hyun Kim, Lauren E. Henke, Alex T. Price Tags: Original Article Source Type: research